Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 2154 • ACR Convergence 2023
Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs
Sebastian Ibanez Vodnizza¹, María Paz Poblete², María Francisca Valenzuela³, María Magdalena Canals², Dominga García² and Carla Jaque³, ¹Clinica Alemana de Santiago / Facultad de Medicina Universidad del Desarrollo-CAS, Santiago, Chile, ²Hospital Padre Hurtado / Facultad de Medicina Universidad del Desarrollo-CAS, Santiago, Chile, ³Hospital Padre Hurtado, Santiago, Chile
Background/Purpose: In Chile, patients with rheumatoid arthritis (RA) can apply to receive state-funded biological or JAK inhibitor treatment if they have failed (defined as a…
Abstract Number: 2410 • ACR Convergence 2023
Tocilizumab versus Methotrexate in Giant Cell Arteritis: A Retrospective Study to Compare Efficacy and Rapidity of These Steroid-sparing Agents in GCA Patients
Luca Quartuccio Quartuccio¹, Elena Treppo², Maria De Martino³, Maria Pillon¹, Simone Perniola⁴, Dario Bruno⁴, Miriam Isola³ and Elisa Gremese⁴, ¹Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, ²Physician, Moimacco, Italy, ³Institute of Statistics, Department of Medicine, University of Udine, Udine, Italy, ⁴Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Roma, Italy
Background/Purpose: Glucocorticoids (GCs) are still the mainstay of treatment of Giant Cell Arteritis (GCA). Although GCs are highly effective in GCA, it is well documented…
Abstract Number: 110 • 2023 Pediatric Rheumatology Symposium
Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Tania Watts¹, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne Benseler⁷ and Rae Yeung⁸, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁴Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health; Department of Molecular Genetics, University of Toronto, Toronto, ON, ⁶Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Québec, Canada; Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Paediatrics, The Alberta Children’s Hospital, Calgary, AB, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare antibody responses to COVID-19 vaccines among children with autoimmune diseases taking different classes of immunosuppressantsMethods: A prospective observational study was conducted at…
Abstract Number: 118 • 2023 Pediatric Rheumatology Symposium
Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis
Natalia Shevchenko and Olga Pavlova, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
Background/Purpose: Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) on long-term…
Abstract Number: L09 • ACR Convergence 2022
Impact on Access to Methotrexate in the Post-Roe Era
Kristin Wipfler¹, Adam Cornish¹, Rebecca Schumacher², Yomei Shaw³, Patricia Katz⁴ and Kaleb Michaud⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases, Santa Fe, NM, ⁴UCSF, San Rafael, CA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Methotrexate is the first line therapy for RA and is used to treat several other rheumatic and non-rheumatic disorders. In high doses, it can…
Abstract Number: 0274 • ACR Convergence 2022
Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset
Sabina Ciciriello¹, Geoffrey Littlejohn², Tamas Treuer³, Kathryn Gibson⁴, Peter Youssef⁵, Paul Bird⁶, Catherine OSullivan⁷, Tegan Smith⁸ and Claire Deakin⁹, ¹Melbourne Health, Melbourne, Australia, ²OPAL Rheumatology Ltd, Melbourne, Australia, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indianapolis, United States of America, Sydney, Australia, ⁵University of Sydney, Sydney, Australia, ⁶University of New South Wales, Sydney, Australia, ⁷OPAL Rheumatology Ltd, Sydney, Australia, ⁸OPAL Rheumatology Ltd, Geelong, Australia, ⁹OPAL Rheumatology Ltd, Mosman, Australia
Background/Purpose: JAK inhibitors (JAKi) have been a major development in treatment for many patients with RA due to their ability to block multiple cytokine pathways…
Abstract Number: 0367 • ACR Convergence 2022
Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use
April Jorge¹, Baijun Zhou¹, yuqing zhang² and Hyon Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Patients with SLE are at increased risk of COVID-19 and its severe outcomes, in part due to the use of immunosuppressants. We sought to…
Abstract Number: 0732 • ACR Convergence 2022
Application of Natural Language Processing to Identify Varicella Zoster Infection in Clinical Notes
Austin Ho¹, Zara Izadi², Gabriela Schmajuk³, Jinoos Yazdany⁴, Suzanne Tamang⁵ and Milena Gianfrancesco⁶, ¹University of California, Berkeley, Berkeley, CA, ²University of California San Francisco, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵Stanford Center for Population Health Sciences, Redwood City, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: Varicella zoster virus (VZV) infection can be associated with significant morbidity in immunosuppressed individuals. However, infections of VZV are often documented in unstructured fields…
Abstract Number: 0913 • ACR Convergence 2022
Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 Vaccine in Patients with Rheumatoid Arthritis
Karam Jabri¹, Linda Burns² and Joseph Grisanti³, ¹University at Buffalo/Catholic Health, Depew, NY, ²Buffalo Rheumatology, Lancaster, NY, ³Buffalo Rheumatology & Medicine, Orchard Park, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of infection compared to healthy subjects (1). This is because of a multifactorial complex…
Abstract Number: 0984 • ACR Convergence 2022
Impact of Hydroxychloroquine on Interferon Pathway Expression of SLE Phenotypic Subsets in the Absence of Background Medications
Colin Mowery, Miles Smith, Kevin Thomas, Susan Macwana, Wade deJager, Stan Kamp, Cristina Arriens, Teresa Aberle, Judith James, Joel Guthridge and Joan Merrill, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Chronic activation of interferon (IFN) pathways is a key driver of immune dysregulation in SLE. Hydroxychloroquine (HCQ) inhibits toll-like receptors 7 and 9 in…
Abstract Number: 1401 • ACR Convergence 2022
Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
George A Karpouzas¹, Zoltan Szekanecz², Eva Baecklund³, Ted Mikuls⁴, Deepak L Bhatt⁵, Harry Shi⁶, Cunshan Wang⁷, Gosford A Sawyerr⁸, Yan Chen⁶, Sujatha Menon⁷, Carol A Connell⁷, Steven R Ytterberg⁹ and Mahta Mortezavi⁸, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁶Pfizer, Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, New York, NY, ⁹Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Uncontrolled RA activity and acute disease flares are associated with higher risk of adverse outcomes, such as cardiovascular (CV) disease, venous thromboembolism (VTE), malignancy,…
Abstract Number: 1737 • ACR Convergence 2022
In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature
Mads Brüner¹, Ulvi Ahmadov¹, Morten Aagaard Nielsen², Lasse Sommer Kristensen¹ and Tue Kragstrup³, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Biomedicine, Aarhus University, and Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark
Background/Purpose: Immune-mediated inflammatory arthritis (IMIA) is a group of diseases characterized by chronic synovitis including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). Some…
Abstract Number: 1992 • ACR Convergence 2022
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Page Moore³, Elizabeth Kohl³, Bernice Gershenson³, Oksana Pugach³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
Abstract Number: PP25 • ACR Convergence 2022
From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective
Shung Chiu¹ and Mei Nee Chiu², ¹Spondylitis Association of America, Ludhiana, Punjab, India, ²University Institute of Pharmaceutical Sciences, Panjab University, Ludhiana, Punjab, India
Background/Purpose: From being a table tennis champion to getting into medical school, I thought my life was smooth sailing. But little did I know it…
Abstract Number: 0029 • ACR Convergence 2022
Characterizing the Anti-fibrotic Effect of Tofacitinib in TGF-β Stimulated Fibroblast-like Synoviocytes from Patients with OA
Sofie Falkenløve Madsen¹, Sarah Madsen², Elle Hollaar³, Thorbjørn Gantzel⁴, Anne-Christine Bay-Jensen³ and Christian Thudium³, ¹University of Copenhagen / Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, University of Copenhagen, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Gentofte Hospital, Gentofte, Denmark
Background/Purpose: Many osteoarthritis (OA) patients develop fibrosis of the synovial membrane leading to joint swelling, stiffness, and pain. Synovial fibroblasts activated in the synovial membrane…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].